C12Y301/03001

ALKALINE PHOSPHATASE FUSION ANTIBODY AND METHOD FOR PRODUCING THE SAME, AND IMMUNOASSAY METHOD
20210371867 · 2021-12-02 · ·

Disclosed is a method for producing an alkaline phosphatase fusion antibody, comprising: culturing a cell comprising an expression vector comprising a gene encoding alkaline phosphatase derived from bovine small intestine or Shewanella bacterium and a gene encoding an antibody in a medium comprising a zinc ion, and acquiring an alkaline phosphatase fusion antibody expressed by the cell.

ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS
20220202914 · 2022-06-30 ·

The present invention relates to methods and compositions for preventing, treating, or reducing chemotherapy treatment-mediated side effects, including gastrointestinal (GI) side effects, comprising administering to a subject intestinal alkaline phosphatases (IAP).

Manufacturing of alkaline phosphatases

A method for producing a recombinant polypeptide, comprising: (a) providing a 100 L to 25,000 L fed-batch bioreactor comprising (i) cells capable of expressing the recombinant polypeptide asfotase alfa (SEQ ID NO: 1), and (ii) a culture medium suitable for conducting such expression, the culture medium comprising about 25 μM to about 300 μM zinc; (b) culturing the cells under conditions suitable to express the recombinant asfotase alfa wherein the pH of the culture medium is about 6.7 to about 7.1, and wherein zinc is added into said culture medium such that the zinc concentration in the culture medium is maintained at a concentration of about 25 μM to about 300 μM of zinc.

Alkaline phosphatase agents for treatment of neurodevelopmental disorders

Compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders, are described.

Recombinant microorganism for producing citicoline and method for producing citicoline

The present invention provides a recombinant microorganism for producing citicoline and a method for producing citicoline by using the recombinant microorganism, wherein genes for degradation and utilization of citicoline, choline, and phosphocholine are knocked out, In addition, a pyrimidine nucleoside synthesis pathway is genetically engineered to remove feedback inhibition to the synthesis pathway. A yield of more than 20 g/L of citicoline can be obtained with recombinant strains in a 5-liter fermenter by means of a biological fermentation method, achieving industrial mass production with low citicoline production costs and less pollution; therefore, the method is a simple, environmentally friendly and has a relatively high promotion and application value.

MANUFACTURING OF GLYCOPROTEINS

A method of producing recombinant alkaline phosphatase comprising control of production parameters, particularly harvest clarified culture fluid (HCCF) and filtration pool (UFDF), to provide a defined total sialic acid content.

COMPOSITIONS AND METHODS FOR ENZYME IMMOBILIZATION

The present disclosure relates to compositions of immobilized enzymes on the surface of achromosomal and/or anucleate cells and uses thereof. In particular, the present disclosure provides genetically engineered minicells with enzymes self-assembled on their surface. The immobilized enzymes on the surface of achromosomal and/or anucleate minicells, has agricultural, industrial, and environmental applications due to their improved stability durability and, reusability. Also, provided are methods for producing and purifying enzyme-immobilized minicells.

BROAD-BASED THERAPEUTIC FOR INACTIVATING COVID-19 AND OTHER VIRAL PATHOGENS USING CHEMILUMINESCENCE-ACTIVATED COMPOUNDS ENCAPSULATED IN NANOPARTICLES
20220152203 · 2022-05-19 · ·

Method and apparatus for producing a broad-spectrum therapeutic for inactivating multiple coronavirus strains including COVID-19. The present invention generates an in situ light source which can inactivate the coronavirus within the body without damaging host cells. This invention couples chemiluminescence-generating compounds with various light-sensitive anti-viral compounds. When activated by chemiluminescence-generated light, the anti-viral compounds inactivate nearby virus particles. In one aspect, the coupled components are co-encapsulated in polymer nanospheres for oral and intranasal delivery. In another aspect of the invention, the coupled components are co-encapsulated in phospholipid nanosomes for intravenous delivery.

ENHANCING BLOOD-BRAIN BARRIER DRUG TRANSPORT BY TARGETING ENDOGENOUS REGULATORS
20230257480 · 2023-08-17 ·

Provided herein are methods and compositions for increasing blood-brain barrier permeability in a subject to enhance blood-brain barrier drug transport and methods and composition for identifying agents that regulate blood-brain barrier permeability.

INTESTINAL ALKALINE PHOSPHATASES AND METHODS OF USE IN INHIBITING LIVER FIBROSIS
20230302098 · 2023-09-28 ·

The present disclosure relates, inter alia, to therapeutic alkaline phosphatases for the treatment of liver fibrosis.